Neurocrine Biosciences price target raised to $25 from $15 at Deutsche Bank

Deutsche Bank believes that Neuricrine has several key catalysts over the next 12 months. The firm thinks that investors are underestimating the potential of the company's Elagolix drug in uterine fibroids. Deutsche keeps a Buy rating on the stock.